Cargando…

A pilot study: Validation of dried blood spots (DBS) to assess SARS-CoV2 IgG antibody immunoassays in underserved minority population

Underserved, low-income, rural and certain migrant populations have greater risks and higher incidences of Coronavirus disease 2019 (COVID-19) than more privileged populations. Current in-person testing methods have limitations, namely exposure risk, a requirement of accessible transportation to hea...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoo, Ji Youn, De, Sai Lata, Sarkar, Anujit, Adams, John H., Groer, Maureen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029335/
https://www.ncbi.nlm.nih.gov/pubmed/36974321
http://dx.doi.org/10.1016/j.heliyon.2023.e14729
_version_ 1784910120118910976
author Yoo, Ji Youn
De, Sai Lata
Sarkar, Anujit
Adams, John H.
Groer, Maureen
author_facet Yoo, Ji Youn
De, Sai Lata
Sarkar, Anujit
Adams, John H.
Groer, Maureen
author_sort Yoo, Ji Youn
collection PubMed
description Underserved, low-income, rural and certain migrant populations have greater risks and higher incidences of Coronavirus disease 2019 (COVID-19) than more privileged populations. Current in-person testing methods have limitations, namely exposure risk, a requirement of accessible transportation to healthcare facilities, and economic barriers. Dried blood spots (DBS) samples are widely used for diagnostics in many infectious diseases including Rabies, HIV, Ebola viruses and newborn screening. Our goal was to determine the accuracy and reliability of measuring COVID-19 IgG in DBS compared to paired plasma samples in a population with known infection status and then apply this method to screen an underserved minority population with high risk for COVID-9 infection (unvaccinated, pregnant, low income, Hispanic women). To optimize the assay, we tested 22 nonpregnant women, 12 with positive prior PCR testing for SARS-CoV2 infection and 10 with negative PCR results. After the assay was optimized, we tested the assay in a vulnerable population with a high risk for infection, who were 52 Hispanic pregnant women without prior PCR testing or vaccination. DBS assay results in both groups showed an agreement of 100% with paired plasma samples. The availability of a DBS assay could enable people who may not have access or transportation to healthcare facilities to use DBS as a COVID-19 testing vehicle.
format Online
Article
Text
id pubmed-10029335
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-100293352023-03-21 A pilot study: Validation of dried blood spots (DBS) to assess SARS-CoV2 IgG antibody immunoassays in underserved minority population Yoo, Ji Youn De, Sai Lata Sarkar, Anujit Adams, John H. Groer, Maureen Heliyon Research Article Underserved, low-income, rural and certain migrant populations have greater risks and higher incidences of Coronavirus disease 2019 (COVID-19) than more privileged populations. Current in-person testing methods have limitations, namely exposure risk, a requirement of accessible transportation to healthcare facilities, and economic barriers. Dried blood spots (DBS) samples are widely used for diagnostics in many infectious diseases including Rabies, HIV, Ebola viruses and newborn screening. Our goal was to determine the accuracy and reliability of measuring COVID-19 IgG in DBS compared to paired plasma samples in a population with known infection status and then apply this method to screen an underserved minority population with high risk for COVID-9 infection (unvaccinated, pregnant, low income, Hispanic women). To optimize the assay, we tested 22 nonpregnant women, 12 with positive prior PCR testing for SARS-CoV2 infection and 10 with negative PCR results. After the assay was optimized, we tested the assay in a vulnerable population with a high risk for infection, who were 52 Hispanic pregnant women without prior PCR testing or vaccination. DBS assay results in both groups showed an agreement of 100% with paired plasma samples. The availability of a DBS assay could enable people who may not have access or transportation to healthcare facilities to use DBS as a COVID-19 testing vehicle. Elsevier 2023-03-21 /pmc/articles/PMC10029335/ /pubmed/36974321 http://dx.doi.org/10.1016/j.heliyon.2023.e14729 Text en © 2023 The Authors
spellingShingle Research Article
Yoo, Ji Youn
De, Sai Lata
Sarkar, Anujit
Adams, John H.
Groer, Maureen
A pilot study: Validation of dried blood spots (DBS) to assess SARS-CoV2 IgG antibody immunoassays in underserved minority population
title A pilot study: Validation of dried blood spots (DBS) to assess SARS-CoV2 IgG antibody immunoassays in underserved minority population
title_full A pilot study: Validation of dried blood spots (DBS) to assess SARS-CoV2 IgG antibody immunoassays in underserved minority population
title_fullStr A pilot study: Validation of dried blood spots (DBS) to assess SARS-CoV2 IgG antibody immunoassays in underserved minority population
title_full_unstemmed A pilot study: Validation of dried blood spots (DBS) to assess SARS-CoV2 IgG antibody immunoassays in underserved minority population
title_short A pilot study: Validation of dried blood spots (DBS) to assess SARS-CoV2 IgG antibody immunoassays in underserved minority population
title_sort pilot study: validation of dried blood spots (dbs) to assess sars-cov2 igg antibody immunoassays in underserved minority population
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029335/
https://www.ncbi.nlm.nih.gov/pubmed/36974321
http://dx.doi.org/10.1016/j.heliyon.2023.e14729
work_keys_str_mv AT yoojiyoun apilotstudyvalidationofdriedbloodspotsdbstoassesssarscov2iggantibodyimmunoassaysinunderservedminoritypopulation
AT desailata apilotstudyvalidationofdriedbloodspotsdbstoassesssarscov2iggantibodyimmunoassaysinunderservedminoritypopulation
AT sarkaranujit apilotstudyvalidationofdriedbloodspotsdbstoassesssarscov2iggantibodyimmunoassaysinunderservedminoritypopulation
AT adamsjohnh apilotstudyvalidationofdriedbloodspotsdbstoassesssarscov2iggantibodyimmunoassaysinunderservedminoritypopulation
AT groermaureen apilotstudyvalidationofdriedbloodspotsdbstoassesssarscov2iggantibodyimmunoassaysinunderservedminoritypopulation
AT yoojiyoun pilotstudyvalidationofdriedbloodspotsdbstoassesssarscov2iggantibodyimmunoassaysinunderservedminoritypopulation
AT desailata pilotstudyvalidationofdriedbloodspotsdbstoassesssarscov2iggantibodyimmunoassaysinunderservedminoritypopulation
AT sarkaranujit pilotstudyvalidationofdriedbloodspotsdbstoassesssarscov2iggantibodyimmunoassaysinunderservedminoritypopulation
AT adamsjohnh pilotstudyvalidationofdriedbloodspotsdbstoassesssarscov2iggantibodyimmunoassaysinunderservedminoritypopulation
AT groermaureen pilotstudyvalidationofdriedbloodspotsdbstoassesssarscov2iggantibodyimmunoassaysinunderservedminoritypopulation